CoChat

Effects of Food and Drug Administration‐approved medications for Alzheimer's disease on clinical progression

Open access
Mielke, Michelle M., Leoutsakos, Jeannie‐Marie, Corcoran, Chris D., Green, Robert C., Norton, Maria C., Welsh‐Bohmer, Kathleen A., Tschanz, JoAnn T., Lyketsos, Constantine G. · 2012 · Alzheimer's & Dementia
Cited by 52

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Background: Observational studies suggest that cholinesterase inhibitors and/or memantine may delay clinical progression of Alzheimer's disease (AD) in 40% of individuals taking the medications. Given this response and existence of side effects, we sought to quantify medication use and benefits in a population‐based study of incident AD cases. Methods: The Cache County Dementia Progression Study enrolled and followed a cohort of 327 incident AD cases for a maximum of 9 years. Drug exposure was expressed using a persistency index (PI), calculated as total years of drug use divided by total years of observation. Linear mixed‐effects models examined PI, and interactions with sex and apolipoprotein E (APOE) as predictors of clinical progression on the Mini‐Mental State Examination and Clinical Dementia Rating‐Sum of Boxes. Results: A total of 69 participants (21.1%) reported having ever used cholinesterase inhibitors or memantine. There was a strong three‐way interaction between PI, sex, and time. Among women, a higher PI (i.e., greater duration of use) of cholinesterase inhibitors was associated with slower progression on the Mini‐Mental State Examination and Clinical Dementia Rating‐Sum of Boxes, particularly among those with an APOE ε4 allele. In contrast, higher PI was associated with faster progression in males. Conclusion: A low percentage of individuals with AD in the community are taking cholinesterase inhibitors or memantine. This study suggests that women, particularly those with an APOE ε4 allele, may benefit the most from these medications. With the newly approved increased dose of donepezil, it will be imperative to determine whether a higher dose is needed in men or whether other factors warrant consideration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2011.02.011

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 52

Metadata

Authors
Mielke, M. M., Leoutsakos, J., Corcoran, C. D., Green, R. C., Norton, M. C., Welsh‐Bohmer, K. A., Tschanz, J. T., & Lyketsos, C. G.
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2012-02-03
Volume
8
Issue
3
Pages
180-187
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W2766184965
Cited by
52
References
6
FWCI
1.64
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.